BIIB trades 8.1% below Wall Street's consensus target of $245.88.
Last 12 months price action with 12-month analyst target path
The base valuation assumes BIIB achieves its forward estimates and maintains a stable P/E multiple of 18.3x. This scenario reflects the blended consensus of 49 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, Biogen Inc. (BIIB) has a Wall Street consensus price target of $245.88, based on estimates from 49 covering analysts. With the stock currently trading at $227.53, this represents a potential upside of +8.1%. The company has a market capitalization of $33.62B.
Analyst price targets range from a low of $175.00 to a high of $300.00, representing a 51% spread in expectations. The median target of $246.50 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 31 analysts rating the stock as a Buy or Strong Buy,17 rating it Hold, and 1 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, BIIB trades at a trailing P/E of 25.8x and forward P/E of 18.3x. Analysts expect EPS to grow +121.1% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $281.23, with bear and bull scenarios of $177.17 and $370.54 respectively. Model confidence stands at 50/100, reflecting moderate uncertainty in projections.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 REGNRegeneron Pharmaceuticals, Inc. | $82.6B | $801.82 | $827.71 | +3.2% | Buy | 14.7x | 49 |
 VRTXVertex Pharmaceuticals Incorporated | $131.0B | $516.34 | $559.33 | +8.3% | Buy | 27.6x | 56 |
 BMRNBioMarin Pharmaceutical Inc. | $12.0B | $62.21 | $90.88 | +46.1% | Buy | 12.4x | 41 |
 ALNYAlnylam Pharmaceuticals, Inc. | $32.9B | $246.51 | $347.33 | +40.9% | Buy | 36.9x | 52 |
 GILDGilead Sciences, Inc. | $187.9B | $151.37 | $150.00 | -0.9% | Buy | — | 58 |
 AMGNAmgen Inc. | $219.2B | $406.09 | $393.72 | -3.0% | Buy | 17.6x | 41 |
 INCYIncyte Corporation | $25.3B | $124.64 | $130.07 | +4.4% | Buy | 33.1x | 44 |
 IONSIonis Pharmaceuticals, Inc. | $7.3B | $43.93 | $86.25 | +96.3% | Buy | — | 33 |
 ACADACADIA Pharmaceuticals Inc. | $4.4B | $25.43 | $33.83 | +33.0% | Buy | 41.1x | 37 |
 LLYEli Lilly and Company | $1.1T | $1152.70 | $1343.07 | +16.5% | Buy | 31.7x | 45 |
Quick answers to the most common questions about buying BIIB stock.
The consensus price target for BIIB is $245.88, close to the current price of $227.53 (8.1% implied move). Based on 49 analyst estimates, the stock appears fairly valued near current levels.
BIIB has a consensus rating of "Buy" based on 49 Wall Street analysts. The rating breakdown is predominantly bullish, with 31 Buy/Strong Buy ratings. The consensus 12-month price target of $245.88 implies 8.1% upside from current levels.
With a forward P/E of 18.3233x, BIIB trades at a relatively low valuation. The consensus target of $245.88 implies 8.1% appreciation, suggesting the market may be pricing in risks.
The most bullish Wall Street analyst has a price target of $300 for BIIB, while the most conservative target is $175. The consensus of $245.88 represents the median expectation. Our quantitative valuation model projects a bull case target of $371 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
BIIB is heavily covered by Wall Street, with 49 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 31 have Buy ratings, 17 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month BIIB stock forecast based on 49 Wall Street analysts shows a consensus price target of $245.88, with estimates ranging from $175 (bear case) to $300 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $281, with bear/bull scenarios of $177/$371.
Our quantitative valuation model calculates BIIB's fair value at $281 (base case), with a bear case of $177 and bull case of $371. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 50/100.
BIIB trades at a forward P/E ratio of 18.3x based on next-twelve-months earnings estimates compared to a trailing P/E of 25.8x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
BIIB appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $245.88 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
BIIB analyst price targets range from $175 to $300, a 51% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $245.88 consensus represents the middle ground. Our model's $177-$371 range provides an independent fundamental perspective.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.